Tadalafil
Code | Size | Price |
---|
TAR-T1398-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1398-25mg | 25mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1398-50mg | 50mg | £129.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1398-100mg | 100mg | £160.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1398-200mg | 200mg | £232.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Tadalafil is a carboline-based compound with vasodilatory activity. Tadalafil selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase- (PDE-5)-mediated degradation of cGMP, which is found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis. Inhibition of cGMP degradation by tadalafil results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection.
CAS:
171596-29-5
Formula:
C22H19N3O4
Molecular Weight:
389.4
Pathway:
Metabolism; Apoptosis
Purity:
0.9953
SMILES:
C1N(C(=O)[C@@H]2N(C1=O)[C@@H](c1c(C2)c2c([nH]1)cccc2)c1ccc2c(c1)OCO2)C
Target:
Apoptosis; PDE
References
1. Blount MA, et al. Mol Pharmacol, 2004, 66(1), 144-152.
2. Ring BJ, et al. Clin Pharmacol Ther, 2005, 77(1), 63-75.
3. Vignozzi L, et al. J Sex Med, 2006, 3(3), 419-431.
4. Zhang L, et al. Brain Res, 2006, 1118(1), 192-198.
5. Lysiak JJ, et al. J Urol, 2008, 179(2), 779-785.